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and wide QRS with left bundle branch block 
morphology—despite optimal medical thera‑
py—has clearly been established.1,2 It has to be 
considered though, that a minority of patients 
IntroductIon The pivotal role of cardiac re‑
synchronization therapy (CRT) in symptomatic 
patients with chronic heart failure (HF), severely 

















Background Current guidelines recommend avoiding apical left ventricular (LV) pacing for cardiac 
resynchronization therapy (CRT).
aims We investigated the feasibility of nonapical pacing with the current quadripolar LV lead technology.
methods We analyzed consecutive patients who received CRT with an LV quadripolar lead. The post­
­implantation position of each electrode of the LV lead was designated as basal, mid, or apical. The pacing 
capture threshold (PCT) and phrenic nerve stimulation (PNS) threshold were assessed for each electrode.
results We enrolled 168 patients. A total of 8 CRT defibrillators were from Biotronik (with Sentus OTW 
QP leads), 98 were from Boston Scientific (with 21 Acuity X4 Spiral and 77 Acuity X4 Straight leads), and 62 
from St. Jude Medical (with Quartet leads). The median (interquartile range) number of electrodes at nonapical 
segments per patient was 3 (1–4) with Biotronik Sentus leads, 4 (3–4) with spiral ­design Boston Scientific 
leads, 4 (3–4) with straight Boston Scientific leads, and 3 (3–4) with St. Jude Medical Quartet leads (P = 0.045). 
Three patients (38%) with Biotronik Sentus leads, 21 (100%) with spiral ­design Boston Scientific leads, 69 
(90%) with straight ­design Boston Scientific leads, and 49 (79%) with St. Jude Medical Quartet leads (P <0.001) 
had at least 1 electrode located at nonapical segments linked with a PNS ­PCT safety margin of more than 
2 V. During the 6­month follow ­up, PNS was detected in 4 patients and was eliminated with reprogramming. 
No significant changes in PCT were detected during follow ­up.
conclusions Quadripolar leads allowed nonapical pacing with acceptable electrical parameters in 
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the local Ethics Committee. The CRT ‑Ds were 
implanted according to the standard practice of 
the individual center. Lead implantation strat‑
ified according to center preference is shown in 
Supplementary material, Table S1. A quadripolar 
LV lead, chosen by the implanting physician, was 
employed in all patients. The LV leads were de‑
ployed in the lateral or posterolateral branches of 
the coronary sinus. A preimplantation coronary 
venous angiogram was performed in at least 2 or‑
thogonal views (left anterior oblique, 20 ° to 40 °, 
and right anterior oblique, 20 ° to 40 °). The final 
position of the LV lead was assessed with postim‑
plantation fluoroscopic images in the same views. 
The positions of the LV leads on the LV surface 
were classified as basal, midventricular, or api‑
cal in the LV “long axis,” and as anterior, lateral, 
or posterior in the LV “short axis.”10,11 The pacing 
capture threshold (PCT) was measured for each 
electrode, in either a bipolar or unipolar con‑
figuration, at 7.5 V or less, using a 0.5‑ms pulse 
width. The presence of phrenic nerve stimula‑
tion (PNS) was evaluated by the same tests. In 
the interest of simplification, for the results of 
each electrode used as a cathode, we selected 
the pacing vector (cathode ‑anode couple) asso‑
ciated with the best electrical performance, de‑
fined as the largest PNS ‑PCT difference. A PNS‑
‑PCT difference greater than 2 V was considered 
acceptable in our evaluation.12 During hospital‑
ization, the optimization of pacing parameters 
and drug therapy was based on clinical evalua‑
tion. After CRT ‑D implantation and discharge, 
follow ‑up was performed according to the stan‑
dard practice of the individual center.
Lead characteristics Commercially available 
transvenous leads were used in this study; an ex‑
ample of LV lead positioning is shown in FIGURE 1. 
The leads adopted in this series were Acuity X4 
Spiral (Boston Scientific), Acuity X4 Straight 
(Boston Scientific), Quartet (St. Jude Medical), 
and Sentus OTW QP (Biotronik). The lead mod‑
els differed in terms of the fixation design (a 
straight lead body for the Acuity X4 Straight, 
an S ‑curve design for the Sentus OTW QP and 
the  Quartet, and a  3‑dimensional helix for 
the Acuity X4 Spiral), tip diameter (2.6F for 
the Acuity family and 4F for both Sentus OTW 
QP and Quartet), maximum interelectrode spac‑
ing (36 mm for the Acuity X4 Straight, 47 mm for 
the Quartet, 50 mm for the Acuity X4 Spiral, and 
61 mm for the Sentus OTW QP), and number of 
programmable pacing vectors (12 with the Bio‑
tronik system, 17 with the Boston Scientific sys‑
tems, and 10 with the St. Jude Medical system).
statistical analysis Continuous data are ex‑
pressed as means (SD) for normally distribut‑
ed continuous variables, or medians and inter‑
quartile ranges in the case of skewed distribu‑
tion. The normality of distributions was tested 
(approximately 34%) may show minimal clini‑
cal improvement after CRT implantation, with 
a progression in the New York Heart Associa‑
tion (NYHA) status demonstrated in about 51% 
of patients randomized to CRT as compared with 
35% of controls (incremental effect 16%).3,4 Other 
than peri ‑implant characteristics, QRS duration, 
and QRS morphology,5 suboptimal positioning 
of the LV lead has been proposed as one possible 
cause of nonresponse to CRT.6 The MADIT ‑CRT 
(Multicenter Automatic Defibrillator Implanta‑
tion Trial ‑Cardiac Resynchronization Therapy) 
has shown that patients who undergo CRT im‑
plantation and have the LV lead positioned in 
the basal or mid ‑ventricular regions have a low‑
er risk of HF hospitalization and death than pa‑
tients in whom the LV lead is placed in apical po‑
sitions.7 Since ventricular electrical delay at the 
stimulation site is the most important mecha‑
nism to enhance CRT response in the presence 
of left bundle branch block,8 pacing from mid‑
‑ventricular or basal regions that have been iden‑
tified as the latest activated segments in patients 
with ventricular conduction disturbances may 
improve outcomes and quality of life in patients 
with HF. Moreover, an apical position of the LV 
lead may be in close proximity to the right ven‑
tricular lead, reducing the interelectrode distance 
and precluding resynchronization. Consequently, 
the current recommendations advocate avoiding 
apical LV pacing for CRT.3 Furthermore, captur‑
ing a larger area of LV with multipoint pacing via 
quadripolar leads is associated with a significant 
reduction in cumulative HF hospitalizations and 
related costs after 1 and 2 years of follow ‑up.9 In 
the present study, we sought to compare some 
currently available quadripolar leads targeting 
midventricular or basal LV regions.
Methods Patient selection, device implan‑
tation, and follow ‑up Consecutive adult pa‑
tients successfully implanted with a CRT defi‑
brillator (CRT ‑D) were enrolled in 9 different 
institutions. The patients gave their written in‑
formed consent and the study was approved by 
whAt’s new?
This multicenter study is the first reported experience to compare the per­
formance of the quadripolar left ventricular leads currently available on 
the market. These leads delivered effective pacing at nonapical left ventricular 
segments in the majority of patients, ensuring acceptable electrical parameters 
and therefore potentially leading to a lower risk of hospitalizations and death 
related to heart failure. Nonetheless, differences exist among the currently 
available electrode systems. Spiral ­design leads may have better electrical 
performance at the proximal tip than at the distal tip and seem to have a greater 
number of effectively usable nonapical electrodes. These findings need to be 
properly assessed by evaluating the differences among the currently available 
systems according to their distinct designs and by characterizing the clinical 
long ­term performance of these leads.
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A 2‑tailed P value of less than 0.05 was consid‑
ered significant for all tests (adjusted for multi‑
ple testing with Bonferroni correction; level of 
significance, 0.008). The STATISTICA software, 
version 7.1 (StatSoft, Inc., Dell Inc., Round Rock, 
Texas, United States) was used for the analysis.
resuLts study population A total of 168 
CRT ‑Ds were implanted in consecutive patients 
with HF and reduced ejection fraction. All pa‑
tients were included in the analysis. The base‑
line clinical variables are summarized in TABLE 1. 
Eight CRT ‑Ds were from Biotronik (with Sen‑
tus OTW QP leads), 98 from Boston Scientif‑
ic (with 21 Acuity X4 Spiral and 77 Acuity X4 
Straight leads), and 62 from St. Jude Medical 
(with Quartet lead).
Positioning of left ventricular leads and lo‑
cation of pacing electrodes The final loca‑
tions of the LV lead tips are summarized in FIGURE 2. 
Specifically, the tip of the LV lead was deployed 
in an apical LV region in 90 patients (54%): 4 
(50%) with the Biotronik Sentus, 9 (43%) with 
the Boston Scientific Acuity X4 Spiral, 35 (45%) 
with the Boston Scientific Acuity X4 Straight, 
and 42 (68%) with the St. Jude Medical Quar‑
tet (P = 0.04 overall). The spiral ‑design lead was 
more likely to target the basal left ventricle. This 
area has indeed been shown to provide better 
clinical outcomes. The distribution of all avail‑
able pacing electrodes (1 distal tip and 3 proxi‑
mal rings) across the LV segments is presented in 
FIGURE 3. The median number of electrodes at non‑
apical segments per patient was higher with both 
the spiral ‑design (4 [3–4]) and straight (4 [3–
4]) Boston Scientific leads than with the other 
models of leads: Biotronik Sentus (3 [1–4]) and 
St. Jude Medical Quartet (3 [3–4]) (P = 0.045 
overall; the Kruskal ‑Wallis test followed by pair‑
wise comparisons).
by means of the nonparametric Kolmogorov‑
‑Smirnov test. Categorical data are expressed 
as numbers and percentages. Differences be‑
tween continuous variables were analyzed us‑
ing the t test for normally distributed variables 
and the Mann ‑Whitney test or the Wilcoxon non‑
parametric test for independent or paired sam‑
ples, respectively, for non‑normally distributed 
variables. Differences in proportions were com‑
pared with the χ2 test or the Fisher exact test, 
as appropriate. One ‑way analysis of variance or 
the Kruskal ‑Wallis test was used to assess dif‑
ferences among groups, followed by the Student‑
‑Neuman ‑Keuls test for post hoc comparisons. 
a B
Figure 1 Example of left ventricular lead positioning: left anterior oblique (a) and right anterior oblique (B) views of Acuity X4 
Spiral (Boston Scientific) positioning
Table 1 Demographics and baseline clinical parameters of the study population 
(n = 168)
Parameter Value
Male sex, n (%) 113 (67)
Age, y, mean (SD) 72 (9)
Ischemic heart disease, n (%) 77 (46)
QRS duration, ms, mean (SD) 151 (27)
NYHA class, n (%) II 91 (54)
III 77 (46)
History of atrial fibrillation, n (%) 59 (35)
Hypertension, n (%) 111 (66)
Diabetes, n (%) 48 (28)
Chronic kidney disease, n (%) 49 (29)
Chronic obstructive pulmonary disease, n (%) 44 (26)
LV ejection fraction, %, mean (SD) 29 (6)
LVEDV, ml, mean (SD) 188 (63)
LVESV, ml, mean (SD) 148 (49)
Abbreviations: LV, left ventricular; LVEDV, left ventricular end ­diastolic volume; LVESV, left 
ventricular end ­systolic volume; NYHA, New York Heart Association
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Figure 2 Distribution of the left ventricular lead tip position by lead model: a – Biotronik Sentus (n = 8); B – St. Jude Medical Quartet (n = 62); c – spiral ‑design 
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Figure 3 Distribution of all available pacing electrodes (1 distal tip and 3 proximal rings) over the left ventricular segments by lead model: a – Biotronik Sentus 
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lower total mortality, cardiac mortality, and less 
HF hospitalizations.13 Quadripolar LV leads en‑
able better reverse remodeling than convention‑
al bipolar leads, due to the lower dislodgement 
rate from the targeted stimulation site.14 Hav‑
ing multiple pacing options allows the electro‑
physiologist to deal with the issues represent‑
ed by PNS and high PCT, as well as enhancing 
the likelihood of successfully pacing nonapical 
LV segments. Currently, a multitude of designs 
for quadripolar LV leads are available to the clini‑
cian, including leads allowing multipoint pacing, 
which can shorten the QRS interval, reduce LV 
dyssynchrony, and increase the LV ejection frac‑
tion.15 The distinctive features might result in 
differences in procedural and clinical outcomes 
among different leads, especially in the setting 
of varying coronary sinus anatomy.
This is the first analysis in a real ‑world Eu‑
ropean setting to show that differences exist 
among the currently available leads in their abil‑
ity to target mid ‑ventricular or basal LV regions. 
This multicenter experience shows that the cur‑
rently available quadripolar LV leads can deliv‑
er effective pacing at nonapical LV segments in 
approximately 85% of patients.
The lead models included in this analysis dif‑
fered in regard to several characteristics (eg, 
the fixation design, tip diameter, interelectrode 
spacing, and number of programmable pacing 
vectors) and presented differences in the abili‑
ty to deliver nonapical LV pacing. Specifically, 
spiral ‑design leads had a higher number of ef‑
fectively usable nonapical electrodes. This find‑
ing was somewhat expected, given that the leads 
were not comparable with regard to interelec‑
trode distance and geometry. The spiral lead was 
designed to ensure stability and low PCT even 
if it is not wedged distally; therefore, the tip of 
the lead was less likely to be deployed in an api‑
cal LV region. In addition, the longer spacing be‑
tween the distal and proximal electrodes result‑
ed in a higher probability that the proximal elec‑
trodes would be located at basal segments. Elec‑
trical performance, as expressed by the mean 
electrical performance In the study popu‑
lation, the mean (SD) PCT was 1.6 (1.3) V at the 
tip electrode, 1.3 (0.8) V at ring 1, 1.8 (1.2) V 
at ring 2, and 2.4 (1.6) V at ring 3. The PCT val‑
ues at the distal tip and proximal rings are pre‑
sented in FIGURE 4. With the Biotronik or St. Jude 
Medical leads, the mean PCT was comparable be‑
tween pacing configurations that used the tip or 
a ring as a cathode. By contrast, with the Bos‑
ton Scientific lead models, the adoption of a ring 
as a cathode resulted in lower PCT, in particu‑
lar with the spiral ‑design leads (P <0.001 and 
P = 0.04 for comparisons of spiral ‑design leads 
and straight ‑design leads, respectively).
The median (SD) number of cathodes associated 
with an acceptable pacing configuration (ie, a PNS‑
‑PCT of >2 V) was 4 (3–4): 2 (1–2) with the Biotron‑
ik Sentus, 4 (3–4) with the spiral ‑design Boston 
Scientific, 4 (3–4) with the straight ‑design Boston 
Scientific, and 3 (2–4) with the St. Jude Medical 
Quartet leads (P >0.05, the Kruskal ‑Wallis test). 
The number of patients with at least 1 electrode 
at nonapical segments associated with a PNS ‑PCT 
safety margin of more than 2 V was 142 (85%): 3 
(38%) with the Biotronik Sentus, 21 (100%) with 
the spiral ‑design Boston Scientific, 69 (90%) with 
the straight ‑design Boston Scientific, and 49 (79%) 
with St. Jude Medical Quartet leads (P <0.001 
overall, followed by pairwise comparisons).
Follow ‑up During the 6‑month follow ‑up, PNS 
was detected in 4 patients. For each of them, al‑
ternative acceptable configurations were avail‑
able and the PNS was eliminated after repro‑
gramming. In the study cohort, the median 
change in PCT from baseline to follow ‑up was 
0 V (–0.5 to 0.3) at the tip electrode, 0.2 (–0.2 
to 0.5) at ring 1, 0.1 (–0.2 to 0.5) at ring 2, and 
0.1 (–0.3 to 0.8) at ring 3 (P >0.05 for all chang‑
es; the Wilcoxon nonparametric test).
dIscussIon In CRT implantations, the use 
of quadripolar LV leads have become the first‑
‑line strategy, since their use is associated with 
Tip Tip Tip TipBest-ring Best-ring Best-ring
Biotronik Sentus Straight-design Boston
Scientific
St Jude Medical Quartet
















Figure 4 Pacing capture threshold comparisons between the electrodes at the distal tip and at the best of proximal rings by 
lead model. The circles indicate means and the whiskers indicate SD.
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the need for reintervention, might be partially 
explained by the novelty of our data in compar‑
ison to older reports, corroborating the down‑
ward trend of CRT issues with more recent im‑
plantations, as postulated by Alonso et al.25
Moreover, the programming flexibility of 
quadripolar leads has also been associated with 
fewer hospitalizations and reduced mortality.26 It 
is possible that avoiding the apical region could 
enhance the overall response to CRT therapy,7,27 
making this an even more cost ‑effective strate‑
gy.28,29 These positive results may be explained 
by the latest activated LV segments being pres‑
ent at the mid ‑ventricular or basal regions,8,30 
while more apical pacing sites may be in close 
proximity to the RV lead, precluding resynchro‑
nization. In this study, we confirmed that api‑
cal pacing could be successfully avoided, as we 
evaluated the location of each electrode of the LV 
lead with post ‑implantation fluoroscopic imag‑
es. We tested each electrode (selected as a cath‑
ode) by choosing the pacing vector (the corre‑
sponding anode) associated with the best elec‑
trical performance, that is, the largest PNS ‑PCT 
difference. This resembles the approach used in 
clinical practice, when operators would test more 
pacing configurations to achieve acceptable PCT 
at the best anatomical location. This method is 
also facilitated by contemporary device algo‑
rithms that automatically test multiple pacing 
configurations and suggest viable options at im‑
plantation and at follow ‑up device interrogation.
Limitations Our study has some significant 
limitations. Due to its nonrandomized, retro‑
spective, observational nature, it may be subject 
to confounders and relevant selection bias, al‑
though it should be pointed out that we included 
consecutive patients in order to minimize this is‑
sue. The initial choice of the lead type was based 
on availability at the time of implantation rath‑
er than patient ‑specific variables 7 and the num‑
ber of leads from different producers makes it 
difficult to draw definite conclusions from this 
comparison. Indeed, the sample size in our study 
was relatively small and not balanced between 
the groups. The independent analysis of the pro‑
spectively collected, postoperative fluoroscopic 
images by a core center is simple and widely ap‑
plicable, though it has some limitations.11 Sig‑
nificant differences exist among the designs of 
the currently available electrode systems, es‑
pecially considering the one with a spiral dis‑
tal part and the 3 with a straight ending. In our 
analysis, the straight leads were from 3 manu‑
facturers and had different sizes, designs, and 
intraelectrode distances, thus making our com‑
parison very complicated and unable to provide 
definite conclusions on this topic; the differenc‑
es between lead types require further investi‑
gations. Also, this study does not address lead‑
‑related differences in the overall response to 
pacing threshold at basal ventricular segments, 
was significantly better with the spiral ‑design 
leads. This is attributable to the lead design, 
which was developed to maintain the basal elec‑
trodes in closer contact with the vessel lumen. 
Nonetheless, although the pacing values seem 
to favor spiral leads, the small difference detect‑
ed may not significantly impact clinical practice.
Our results confirm the previous findings of 
the LILAC (Left Ventricular Three ‑Dimensional 
Quadripolar Lead Acute Clinical) study,16 which 
evaluated the acute performance of 3 quadripo‑
lar LV prototype leads and found that acceptable 
PCT without PNS was achieved in the first im‑
planted target vein with a spiral lead design in 
more than 90% of patients. Indeed, it was shown 
that an excellent contact between the electrode 
and the myocardium—at least at 1 proximal 
electrode, leading to adequate PCT—is possi‑
ble with a 3‑dimensional spiral design, irrespec‑
tive of the diameter of the vein or the location of 
the lead (proximal or distal). Moreover, LV stim‑
ulation at basal sites might also be the ideal lo‑
cation to manage PNS, as PNS was found to oc‑
cur more frequently at apical or mid LV sites.17,18 
Similarly, the NAVIGATE X4 (Evaluation of ACU‑
ITY X4 Quadripolar Coronary Venous Leads 
and RELIANCE 4‑FRONT Defibrillation Leads) 
clinical trial showed lower PCT from proximal 
electrodes spaced around a helical bias of spiral 
leads than from the distal electrode.19 In the tri‑
al, this resulted in devices most commonly per‑
manently programmed to pace from a proximal 
electrode, thereby increasing the probability of 
avoiding pacing from apical regions of the LV.
Positioning LV leads at an effective location is 
a prerequisite for effective CRT. Quadripolar LV 
leads were developed to prevent high PCT and 
PNS by allowing more options in lead placement 
and programming capability. In recent years, 
there has been a growing body of evidence from 
several studies which emphasizes the efficacy of 
quadripolar LV leads; this has led to their wide‑
spread adoption in the clinical setting of CRT, be‑
ing associated with low rates of dislocation and 
PNS at follow ‑up.20‑22 Indeed, while PNS was de‑
tected in 4 of 168 patients (2.4%), no evident and 
significant LV lead dislodgment leading to rein‑
tervention was detected, either immediately af‑
ter the procedure or during the 6‑month follow‑
‑up in our cohort; this was also witnessed by 
PNS resolving after reprogramming in all cas‑
es, although chest x ‑ray data were not system‑
atically collected during follow ‑up. These data 
are in line with other studies that analyzed dis‑
lodgement and malfunction of these leads jointly, 
such as Ghani et al,23 who reported that a glob‑
al rate of LV lead dislodgement or malfunction 
within the first year was 1.4% and Bulava et al,24 
who reported a rate of 1.1% for LV dislodgment 
with a loss of capture and need for repositioning. 
The low rates of complications, circumventing 

































































CRT and lacks clinical data on short‑ and long‑
‑term follow ‑up. Therefore, additional support‑
ing clinical studies with follow ‑up data are re‑
quired to evaluate differences in clinical and pro‑
cedural outcomes among the currently available 
quadripolar leads.
conclusions This multicenter study is the first 
reported experience to compare the performance 
of currently available quadripolar LV leads. As ex‑
pected due to their design, these leads allowed ef‑
fective pacing to be delivered at nonapical LV seg‑
ments in the majority of patients, ensuring accept‑
able electrical parameters and therefore poten‑
tially leading to a lower risk of HF hospitalization 
and death. These leads were invented to provide 
stability of the leads’ location and the ability to 
stimulate from different sites; these features were 
in fact reflected in our data. Additional support‑
ing studies are clearly needed to properly assess 
differences among the currently available sys‑
tems with different designs and to characterize 
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